BOLERO-2
Baseline patient characteristics were well balanced between the 2 treatment arms
| BASELINE PATIENT CHARACTERISTICS1,2 | |||
| Characteristic | AFINITOR + exemestane (n=485) | Placebo + exemestane (n=239) | |
| Median age (range), years | 62 (34-93) | 61 (28-90) | |
| Race* | White | 74% | 78% |
| Asian | 20% | 19% | |
| No adjuvant therapy | 31% | 31% | |
| Visceral disease | 58% | 59% | |
| Measurable disease† | 70% | 68% | |
| Metastatic site | Lung | 30% | 33% |
| Liver | 33% | 30% | |
| Bone | 77% | 77% | |
| Number of metastatic sites | 1 | 32% | 29% |
| 2 | 31% | 34% | |
| ≥3 | 36% | 37% | |
| ECOG performance status | 0 | 60% | 59% |
| 1 | 36% | 35% | |
| 2 | 2% | 3% | |
In BOLERO-2: ~59%of patients had visceral disease1‡
84%of patients had ≥2 sites of metastatic involvement1
21%of patients had bone-only metastases at baseline1
*Race was determined by self-report.
†All other patients had at least 1 mainly lytic bone lesion.
‡AFINITOR is indicated for the treatment of hormone receptor–positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor.
†All other patients had at least 1 mainly lytic bone lesion.
‡AFINITOR is indicated for the treatment of hormone receptor–positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor.
Abbreviations:
aBC, advanced breast cancer; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; HR+, hormone receptor-positive; ECOG, Eastern Cooperative Oncology Group.
aBC, advanced breast cancer; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; HR+, hormone receptor-positive; ECOG, Eastern Cooperative Oncology Group.
References:
1. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.
2. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
1. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.
2. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
*Race was determined by self-report.
†All other patients had at least 1 mainly lytic bone lesion.
‡AFINITOR is indicated for the treatment of hormone receptor–positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor.
†All other patients had at least 1 mainly lytic bone lesion.
‡AFINITOR is indicated for the treatment of hormone receptor–positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor.
Abbreviations:
aBC, advanced breast cancer; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; HR+, hormone receptor-positive; ECOG, Eastern Cooperative Oncology Group.
aBC, advanced breast cancer; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; HR+, hormone receptor-positive; ECOG, Eastern Cooperative Oncology Group.
References:
1. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.
2. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
1. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.
2. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
